In light of the 2 negative bevacizumab trials for up-front GBM, how do you feel about the future of bevacizumab in GBM?
Do you really feel the failure was because people crossed over to bev at progression, or is it simply that bev does not affect overall survival?
Answer from: Radiation Oncologist at Academic Institution
At the 2010 ASTRO meeting, Dr Inder Verma of the Salk Institute gave a very nice keynote address talking about his work using a mouse model of GBM where the GBM cells themselves can morph into vessels as needed, with no expectation of response to anti-VEGF therapy. The work was published a while bac...
Sign in or Register to read more